Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Lebrikiuzmab | Pediatric atopic dermatitis | Phase 3 | Ongoing | Subcutaneous | Immunology |
| Eli Lilly and Company | Vepugratinib - (FORAGER-2) | 1L metastatic urothelial cancer | Phase 3 | Ongoing | oral | Oncology |
| Eli Lilly and Company | Sofetabart Mipitecan | Platinum-sensitive ovarian cancer | Phase 3 | Trial Planned | Oral | Oncology |
| Eli Lilly and Company | Muvalaplin | Heart disease | Phase 3 | Trial Planned | Oral | Cardiology |
| Eli Lilly and Company | Tersolisib (LY4064809) | Advanced breast cancer | Phase 3 | Ongoing | Oral | Oncology |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-1) | Pre-diabetes and obesity or overweight | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Orforglipron - (ATTAIN-PAD) | Peripheral Arterial Disease | Phase 3 | Ongoing | Oral | Cardiology |
| Eli Lilly and Company | VTX958 | Crohn's disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
